85%Confidence
0Views
FDASource
2026-04-21Date
Summary
Another Fresenius Kabi sodium chloride injection recall for sterility issues suggests systemic quality problems across multiple product lines. This recurring pattern may erode customer trust and invite more stringent FDA oversight.
Actionable: Evaluate the cumulative effect of multiple recalls on Fresenius Kabi's operational efficiency and market position in sterile injectables.
AI Confidence: 85%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fres
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now